Beneficial Effects of Torasemide on Systolic Wall Stress and Sympathetic Nervous Activity in Asymptomatic or Mildly Symptomatic Patients With Heart Failure: Comparison With Azosemide

Authors:
  • HIHideo Izawa
    Hideo Izawa
  • TNTakao Nishizawa
    Takao Nishizawa
  • AHAkihiro Hirashiki
    Akihiro Hirashiki
  • YMYosuke Murase
    Yosuke Murase
  • MKMasakazu Kobayashi
    Masakazu Kobayashi
  • SISatoshi Isobe
    Satoshi Isobe
  • XCXian Wu Cheng
    Xian Wu Cheng
  • ANAkiko Noda
    Akiko Noda
  • KNKohzo Nagata
    Kohzo Nagata
  • MYMitsuhiro Yokota
    Mitsuhiro Yokota
  • TMToyoaki Murohara
    Toyoaki Murohara

Abstract
Loop diuretics could adversely influence prognosis due to activation of neurohumoral mechanism in the long term. Previous study showed torasemide, a loop diuretic with anti-aldosteronergic properties, was associated with lower mortality in patients with chronic heart failure (CHF). We evaluated the effects of torasemide, in comparison with azosemide, in patients with CHF. Patients received oral diuretic therapy with torasemide (8 mg/d, n = 15) or azosemide (60 mg/d, n = 15) for 3 months. Torasemide and azosemide were then switched, and the patients were treated for another 3 months. Torasemide treatment induced significant decreases in left ventricular (LV) systolic wall stress (from 259 ± 95 to 232 ± 80 kdyn/cm2) and the plasma level of aldosterone (from 133 ± 61 to 95 ± 50 pg/mL) and was not associated with a change in the plasma level of norepinephrine. In contrast, the plasma level of norepinephrine was significantly increased (from 370 ± 170 to 481 ± 247 pg/mL), whereas LV systolic wall stress was unchanged after azosemide treatment. This study indicates that torasemide treatment reduced LV systolic wall stress without activation of the sympathetic nervous system in patients with CHF. The anti-aldosteronergic properties of torasemide may contribute to its favorable effects.

This publication has 30 references indexed in Scilit: